Yeast Infection Treatment Market Analysis by Azoles, Polygene, and Echinocandin from 2024 to 2034

<p>The global <strong>yeast infection treatment market </strong>was valued at US$ 6158.8 million in 2023. The market is estimated to surge at a CAGR of 5.0%, reaching a valuation of US$ 10031.3 million in 2034. The primary factors driving this market&#39;s expansion include the advent of novel fungal illnesses, as well as the rise in autoimmune disorders and yeast infections.</p><table> <tbody> <tr> <th scope='row'>Attributes</th> <td>Key Insights</td> </tr> <tr> <th scope='row'>Anticipated Market Value (2023A)</th> <td>US$ 6158.8 million</td> </tr> <tr> <th scope='row'>Estimated Yeast Infection Treatment Market Size (2024E)</th> <td>US$ 6479.8 million</td> </tr> <tr> <th scope='row'>Projected Yeast Infection Treatment Market Value (2034F)</th> <td>US$ 10031.3 million</td> </tr> <tr> <th scope='row'>Value-based Yeast Infection Treatment Market CAGR (2024 to 2034)</th> <td>5.0%</td> </tr> </tbody></table><p>Country-wise Insights</p><table> <tbody> <tr> <th scope='row'>Countries</th> <td>Projected CAGR (2024 to 2034)</td> </tr> <tr> <th scope='row'>United States</th> <td>5.2%</td> </tr> <tr> <th scope='row'>China</th> <td>5.4%</td> </tr> <tr> <th scope='row'>Germany</th> <td>4.9%</td> </tr> <tr> <th scope='row'>India</th> <td>5.8%</td> </tr> <tr> <th scope='row'>Japan</th> <td>5.7%</td> </tr> </tbody></table><p>Category-wise Insights</p><table> <tbody> <tr> <th scope='row'>Route of Administration</th> <td>Value-based CAGR</td> </tr> <tr> <th scope='row'>IV/IM</th> <td>5.4%</td> </tr> <tr> <th scope='row'>Oral</th> <td>5.2%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>Form</th> <td>Value-based CAGR</td> </tr> <tr> <th scope='row'>Tablets/ Capsules</th> <td>5.4%</td> </tr> <tr> <th scope='row'>Cream / Ointments</th> <td>5.0%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>Distribution Channel</th> <td>Value-based CAGR</td> </tr> <tr> <th scope='row'>Online Sales</th> <td>6.0%</td> </tr> <tr> <th scope='row'>Retail Pharmacies/ Drug Stores</th> <td>5.5%</td> </tr> </tbody></table>

<p>全球酵母感染治疗市场在2023年价值达到6.1588亿美元。预计该市场规模将呈复合年增长率5.0%迅猛增长，并于2034年达到100.313亿美元。推动该市场扩张的主要因素包括新型真菌性疾病的出现，以及自身免疫性疾病和酵母感染的发病率上升。</p><table> <tbody> <tr> <th scope='row'>属性</th> <td>关键洞察</td> </tr> <tr> <th scope='row'>预计市场价值（2023年预测）</th> <td>6.1588亿美元</td> </tr> <tr> <th scope='row'>预计酵母感染治疗市场规模（2024年预测）</th> <td>6.4798亿美元</td> </tr> <tr> <th scope='row'>预测酵母感染治疗市场规模价值（2034年预测）</th> <td>100.313亿美元</td> </tr> <tr> <th scope='row'>基于价值的酵母感染治疗市场规模复合年增长率（2024年至2034年）</th> <td>5.0%</td> </tr> </tbody></table><p>按国家划分的洞察</p><table> <tbody> <tr> <th scope='row'>国家</th> <td>预测复合年增长率（2024年至2034年）</td> </tr> <tr> <th scope='row'>美国</th> <td>5.2%</td> </tr> <tr> <th scope='row'>中国</th> <td>5.4%</td> </tr> <tr> <th scope='row'>德国</th> <td>4.9%</td> </tr> <tr> <th scope='row'>印度</th> <td>5.8%</td> </tr> <tr> <th scope='row'>日本</th> <td>5.7%</td> </tr> </tbody></table><p>按类别划分的洞察</p><table> <tbody> <tr> <th scope='row'>给药途径</th> <td>基于价值的复合年增长率</td> </tr> <tr> <th scope='row'>静脉/肌内注射</th> <td>5.4%</td> </tr> <tr> <th scope='row'>口服</th> <td>5.2%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>剂型</th> <td>基于价值的复合年增长率</td> </tr> <tr> <th scope='row'>片剂/胶囊</th> <td>5.4%</td> </tr> <tr> <th scope='row'>乳膏/药膏</th> <td>5.0%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>分销渠道</th> <td>基于价值的复合年增长率</td> </tr> <tr> <th scope='row'>在线销售</th> <td>6.0%</td> </tr> <tr> <th scope='row'>零售药店/药品店</th> <td>5.5%</td> </tr> </tbody></table>